Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Atea Pharmaceuticals (AVIR) Leases (2021 - 2026)

Atea Pharmaceuticals' Leases history spans 6 years, with the latest figure at $478000.0 for Q1 2026.

  • Quarterly Leases fell 56.27% to $478000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $478000.0 through Mar 2026, down 56.27% year-over-year, with the annual reading at $634000.0 for FY2025, 48.99% down from the prior year.
  • Leases came in at $478000.0 for Q1 2026, down from $634000.0 in the prior quarter.
  • In the past five years, Leases ranged from a high of $2.9 million in Q1 2022 to a low of $478000.0 in Q1 2026.
  • The 5-year median for Leases is $1.7 million (2024), against an average of $1.7 million.
  • Year-over-year, Leases skyrocketed 1383.85% in 2022 and then tumbled 56.27% in 2026.
  • Atea Pharmaceuticals' Leases stood at $2.4 million in 2022, then dropped by 23.48% to $1.8 million in 2023, then crashed by 32.0% to $1.2 million in 2024, then tumbled by 48.99% to $634000.0 in 2025, then decreased by 24.61% to $478000.0 in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Leases are $478000.0 (Q1 2026), $634000.0 (Q4 2025), and $789000.0 (Q3 2025).